Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Ovarian Cancer treatment details. Biologic therapy. Massachusetts General Hospital, Boston, Mass, United States

Survival: 10.3 months
Toxicity Grade: 3
Treatments: Biologic therapy
Country: United States
City/State/Province: Boston, Mass
Hospital: Massachusetts General Hospital
Journal: Link
Date: 11/2006

Patients: This phase II trial enrolled and treated 37 women with recurrent platinum-resistant ovarian cancer. The average age was 58 years, ranging from 28 to 83.

Treatment: Patients were treated with the monoclonal antibody matuzumab. Twenty-three of the 37 patients received eight or more weeks of therapy.

Toxicity: There were 10 grade 3 adverse events, and they occurred in five patients. These toxicities were headache, abdominal pain, diarrhea, nausea, vomiting, myalgia, acute pancreatitis, dehydration, and intestinal obstruction.

Results: The median overall survival was 10.3 months. For patients that completed eight or more weeks of therapy, the median overall survival was 13.3 months. The authors conclude that ‘matuzumab did not produce any responses in this population of women with heavily pretreated ovarian cancer’.

Support: Supported by a grant from EMD Pharmaceuticals, Inc, a maker of matuzumab.

Correspondence: Dr. M.V. Seiden

E-mail to a Friend Email Physician More Information